Skip to content
lifestyle.cfxmagazine.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
HepaRegeniX
HepaRegeniX Completes Darizmetinib Treatment Phase for First Patient Undergoing Major Liver Resection in Phase 1b Liver Regeneration Study
September 22, 2026
HepaRegeniX Receives Orphan Drug Designation for Darizmetinib for the Prevention of Post-Hepatectomy Liver Failure
August 26, 2026
HepaRegeniX to Present Interim Phase 1b Data for Darizmetinib (HRX215) in a Late-Breaking Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2026
May 22, 2026